Avadel Pharmaceuticals Files 8-K on Financials
| Field | Detail |
|---|---|
| Company | Avadel Pharmaceuticals PLC |
| Form Type | 8-K |
| Filed Date | Nov 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, pharmaceuticals
TL;DR
Avadel dropped an 8-K on Nov 4th covering financials. Check it out.
AI Summary
Avadel Pharmaceuticals plc filed an 8-K on November 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Dublin, Ireland. Avadel Pharmaceuticals is listed under the Pharmaceutical Preparations SIC code.
Why It Matters
This 8-K filing provides investors with an update on Avadel Pharmaceuticals' financial performance and condition, which is crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or adverse events.
Key Players & Entities
- AVADEL PHARMACEUTICALS PLC (company) — Registrant
- November 4, 2025 (date) — Date of Report
- Dublin 2, Ireland (location) — Principal executive offices
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What specific financial information is detailed in this 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are not provided in the header information.
When was this 8-K report filed?
The report was filed on November 4, 2025.
Where are Avadel Pharmaceuticals plc's principal executive offices located?
The principal executive offices are located at 10 Earlsfort Terrace, Dublin 2, Ireland.
What is Avadel Pharmaceuticals plc's Standard Industrial Classification (SIC) code?
The SIC code for Avadel Pharmaceuticals plc is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing mention any changes to the company's name or structure?
The filing notes a former company name, FLAMEL TECHNOLOGIES SA, with a date of name change as April 22, 1996, indicating a past corporate event.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-11-04 16:08:52
Key Financial Figures
- $0.01 — stered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Ma
Filing Documents
- tm2530173d1_8k.htm (8-K) — 26KB
- tm2530173d1_ex99-1.htm (EX-99.1) — 131KB
- 0001104659-25-106273.txt ( ) — 334KB
- avdl-20251104.xsd (EX-101.SCH) — 3KB
- avdl-20251104_lab.xml (EX-101.LAB) — 33KB
- avdl-20251104_pre.xml (EX-101.PRE) — 22KB
- tm2530173d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operation and Financial Condition . On November 4, 2025, Avadel Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.
01
Item 9.01. Exhibits (d) Exhibits 99.1 Press release issued by Avadel Pharmaceuticals plc on November 4, 2025. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVADEL PHARMACEUTICALS PLC By: /s/ Jerad G. Seurer Date: November 4, 2025 Name: Jerad G. Seurer Title: General Counsel & Corporate Secretary